Indefinite Delivery Contract SPE2DX15D9224

DMS Pharmaceutical Group Inc., a woman-owned small business, holds a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at up to $499,999,999 through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military health facilities worldwide. The contract has no set-aside designation.

Under this IDC, DMS Pharmaceutical Group has received multiple firm fixed-price delivery orders for a variety of pharmaceutical products, such as Xtandi, Mirena, Wegovy, Nexplanon, and Novolog Mix. The delivery orders, ranging in value from several hundred dollars to over $4,000, are being performed at DMS Pharmaceutical Group's facility in Park Ridge, Illinois, with ultimate completion dates spanning from early 2024 to mid-2025. These awards demonstrate DMS Pharmaceutical Group's capabilities in providing a diverse portfolio of both common and specialized medications to support the operational requirements of the Department of Defense.